Acetyl-lysine erasers and readers in the control of pulmonary hypertension and right ventricular hypertrophy1

Biochemistry and Cell Biology

Volumn 93, Issue 2, 2015, Pages 149-157

  Stratton, Matthew S ^a   McKinsey, Timothy A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Bromodomain; Epigenetics; HDAC; Pulmonary hypertension; RV hypertrophy

Indexed keywords

ACETYLATION; AMINO ACIDS; GENE EXPRESSION; PATHOLOGY;

BROMODOMAIN; EPIGENETICS; HDAC; PULMONARY HYPERTENSION; RV HYPERTROPHY;

PROTEINS;

ACETIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; BROMODOMAIN AND EXTRA TERMINAL PROTEIN; CYCLOPEPTIDE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; LYSINE; PHARMACOLOGY; PROTEIN; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG; VALPROIC ACID;

ACETYLATION; ANIMAL; ARTERY MUSCLE; CLASSIFICATION; DISEASE MODEL; ENZYMOLOGY; EPIGENETICS; FIBROBLAST; GENETIC EPIGENESIS; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HUMAN; METABOLISM; NONHUMAN; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; REVIEW; SMOOTH MUSCLE FIBER; TRANSCRIPTION REGULATION;

ACETYLATION; ANIMALS; CLASSIFICATION; DISEASE MODELS, ANIMAL; ENZYMOLOGY; EPIGENESIS, GENETIC; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; LYSINE; METABOLISM; PHARMACOLOGY; RATS;

EID: 84964225150     PISSN: 08298211     EISSN: 12086002     Source Type: Journal    
DOI: 10.1139/bcb-2014-0119     Document Type: Review

References (93)

1. Anand P. Brown J.D. Lin C.Y. Qi J. Zhang R. Artero P.C. et al 2013. BET bromodomains mediate transcriptional pause release in heart failure. Cell, 154: 569-582. 10.1016/j.cell.2013.07.013. 23911322.
2. Backs J. Song K. Bezprozvannaya S. Chang S. Olson E.N. 2006. CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J. Clin. Invest. 116: 1853-1864. 10.1172/JCI27438. 16767219.
3. Backs J. Backs T. Bezprozvannaya S. McKinsey T.A. Olson E.N. 2008. Histone deacetylase 5 acquires calcium/calmodulin-dependent kinase II responsiveness by oligomerization with histone deacetylase 4. Mol. Cell. Biol. 28: 3437-3445. 10.1128/MCB.01611-07. 18332106.
4. Bisgrove D.A. Mahmoudi T. Henklein P. Verdin E. 2007. Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proc. Natl. Acad. Sci. U.S.A. 104: 13690-13695. 10.1073/pnas.0705053104. 17690245.
5. Bogaard H.J. Natarajan R. Henderson S.C. Long C.S. Kraskauskas D. Smithson L. et al 2009. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation, 120: 1951-1960. 10.1161/CIRCULATIONAHA.109.883843. 19884466.
6. Bogaard H.J. Mizuno S. Hussaini A.A. Toldo S. Abbate A. Kraskauskas D. et al 2011. Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats. Am. J. Respir. Crit. Care Med. 183: 1402-1410. 10.1164/rccm.201007-1106OC. 21297075.
7. Bradner J.E. West N. Grachan M.L. Greenberg E.F. Haggarty S.J. Warnow T. Mazitschek R. 2010. Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 6: 238-243. 10.1038/nchembio.313. 20139990.
8. Bush E.W. McKinsey T.A. 2010. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors. Circ. Res. 106: 272-284. 10.1161/CIRCRESAHA.109.209338. 20133912.
9. Butler K.V. Kalin J. Brochier C. Vistoli G. Langley B. Kozikowski A.P. 2010. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J. Am. Chem. Soc. 132: 10842-10846. 10.1021/ja102758v. 20614936.
10. Cantoni S. Galletti M. Zambelli F. Valente S. Ponti F. Tassinari R. et al 2013. Sodium butyrate inhibits platelet-derived growth factor-induced proliferation and migration in pulmonary artery smooth muscle cells through Akt inhibition. FEBS J. 280: 2042-2055. 10.1111/febs.12227. 23463962.
11. Cavasin M.A. Demos-Davies K. Horn T.R. Walker L.A. Lemon D.D. Birdsey N. et al 2012. Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circ. Res. 110: 739-748. 10.1161/CIRCRESAHA.111.258426. 22282194.
12. Chen Y. He R. Chen Y. D'Annibale M.A. Langley B. Kozikowski A.P. 2009. Studies of benzamide-and thiol-based histone deacetylase inhibitors in models of oxidative-stress-induced neuronal death: identification of some HDAC3-selective inhibitors. ChemMedChem, 4: 842-852. 10.1002/cmdc.200800461. 19350613.
13. Cho Y.K. Eom G.H. Kee H.J. Kim H.S. Choi W.Y. Nam K.I. et al 2010. Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats. Circ. J. 74: 760-770. 10.1253/circj.CJ-09-0580. 20208383.
14. Chou D.H. Holson E.B. Wagner F.F. Tang A.J. Maglathlin R.L. Lewis T.A. et al 2012. Inhibition of histone deacetylase 3 protects beta cells from cytokine-induced apoptosis. Chem. Biol. 19: 669-673. 10.1016/j.chembiol.2012.05.010. 22726680.
15. Choudhary C. Kumar C. Gnad F. Nielsen M.L. Rehman M. Walther T.C. et al 2009. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science, 325: 834-840. 10.1126/science.1175371. 19608861.
16. Cunliffe V.T. 2008. Eloquent silence: developmental functions of Class I histone deacetylases. Curr. Opin. Genet. Dev. 18: 404-410. 10.1016/j.gde.2008.10.001. 18929655.
17. De Raaf M.A. Hussaini A.A. Gomez-Arroyo J. Kraskaukas D. Farkas D. Happe C. et al 2014. Histone deacetylase inhibition with trichostatin A does not reverse severe angioproliferative pulmonary hypertension in rats (2013 Grover Conference series). Pulm. Circ. 4: 237-243. 10.1086/675986. 25006442.
18. Demos-Davies K.M. Ferguson B.S. Cavasin M.A. Mahaffey J.H. Williams S.M. Spiltoir J.I. et al 2014. HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling. Am. J. Physiol. Heart Circ. Physiol. 307: H252-H258. 10.1152/ajpheart.00149.2014. 24858848.
19. Deroanne C.F. Bonjean K. Servotte S. Devy L. Colige A. Clausse N. et al 2002. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene, 21: 427-436. 10.1038/sj.onc.1205108. 11821955.
20. Fass D.M. Shah R. Ghosh B. Hennig K. Norton S. Zhao W.N. et al 2010. Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin. ACS Med. Chem. Lett. 2: 39-42. 10.1021/ml1001954. 21874153.
21. Filippakopoulos P. Qi J. Picaud S. Shen Y. Smith W.B. Fedorov O. et al 2010. Selective inhibition of BET bromodomains. Nature, 468: 1067-1073. 10.1038/nature09504. 20871596.
22. Fischle W. Dequiedt F. Hendzel M.J. Guenther M.G. Lazar M.A. Voelter W. Verdin E. 2002. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell, 9: 45-57. 10.1016/S1097-2765(01)00429-4. 11804585.
23. Galletti M. Cantoni S. Zambelli F. Valente S. Palazzini M. Manes A. et al 2014. Dissecting histone deacetylase role in pulmonary arterial smooth muscle cell proliferation and migration. Biochem. Pharmacol. 91: 181-190. 10.1016/j.bcp.2014.07.011. 25063234.
24. Gao J. Siddoway B. Huang Q. Xia H. 2009. Inactivation of CREB mediated gene transcription by HDAC8 bound protein phosphatase. Biochem. Biophys. Res. Commun. 379: 1-5. 10.1016/j.bbrc.2008.11.135. 19070599.
25. Gregoretti I.V. Lee Y.M. Goodson H.V. 2004. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338: 17-31. 10.1016/j.jmb.2004.02.006. 15050820.
26. Grozinger C.M. Schreiber S.L. 2000. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc. Natl. Acad. Sci. U.S.A. 97: 7835-7840. 10.1073/pnas.140199597. 10869435.
27. Haggarty S.J. Koeller K.M. Wong J.C. Grozinger C.M. Schreiber S.L. 2003. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. U.S.A. 100: 4389-4394. 10.1073/pnas.0430973100. 12677000.
28. Haldar S.M. McKinsey T.A. 2014. BET-ting on chromatin-based therapeutics for heart failure. J. Mol. Cell. Cardiol. 74C: 98-102. 10.1016/j.yjmcc.2014.05.002. 24838003.
29. Harrison B.C. Kim M.S. van Rooij E. Plato C.F. Papst P.J. Vega R.B. et al 2006. Regulation of cardiac stress signaling by protein kinase d1. Mol. Cell. Biol. 26: 3875-3888. 10.1128/MCB.26.10.3875-3888.2006. 16648482.
30. Heltweg B. Dequiedt F. Marshall B.L. Brauch C. Yoshida M. Nishino N. et al 2004. Subtype selective substrates for histone deacetylases. J. Med. Chem. 47: 5235-5243. 10.1021/jm0497592. 15456267.
31. Humbert M. Morrell N.W. Archer S.L. Stenmark K.R. MacLean M.R. Lang I.M. et al 2004. Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43: 13S-24S. 10.1016/j.jacc.2004.02.029. 15194174.
32. Iwata A. Riley B.E. Johnston J.A. Kopito R.R. 2005. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J. Biol. Chem. 280: 40282-40292. 10.1074/jbc.M508786200. 16192271.
33. Jang M.K. Mochizuki K. Zhou M. Jeong H.S. Brady J.N. Ozato K. 2005. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell, 19: 523-534. 10.1016/j.molcel.2005.06.027. 16109376.
34. Jiang L. Levine R.A. Weyman A.E. 1997. Echocardiographic Assessment of Right Ventricular Volume and Function. Echocardiography, 14: 189-206. 10.1111/j.1540-8175.1997.tb00711.x. 11174944.
35. Kao H.Y. Verdel A. Tsai C.C. Simon C. Juguilon H. Khochbin S. 2001. Mechanism for nucleocytoplasmic shuttling of histone deacetylase 7. J. Biol. Chem. 276: 47496-47507. 10.1074/jbc.M107631200. 11585834.
36. Karolczak-Bayatti M. Sweeney M. Cheng J. Edey L. Robson S.C. Ulrich S.M. et al 2011. Acetylation of heat shock protein 20 (Hsp20) regulates human myometrial activity. J. Biol. Chem. 286: 34346-34355. 10.1074/jbc.M111.278549. 21803775.
37. Lahm A. Paolini C. Pallaoro M. Nardi M.C. Jones P. Neddermann P. et al 2007. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc. Natl. Acad. Sci. U.S.A. 104: 17335-17340. 10.1073/pnas.0706487104. 17956988.
38. Lee J.Y. Koga H. Kawaguchi Y. Tang W. Wong E. Gao Y.S. et al 2010. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J. 29: 969-980. 10.1038/emboj.2009.405. 20075865.
39. Lemercier C. Verdel A. Galloo B. Curtet S. Brocard M.P. Khochbin S. 2000. mHDA1/HDAC5 histone deacetylase interacts with and represses MEF2A transcriptional activity. J. Biol. Chem. 275: 15594-15599. 10.1074/jbc.M908437199. 10748098.
40. Lemon D.D. Horn T.R. Cavasin M.A. Jeong M.Y. Haubold K.W. Long C.S. et al 2011. Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension. J. Mol. Cell. Cardiol. 51: 41-50. 10.1016/j.yjmcc.2011.04.005. 21539845.
41. Li M. Riddle S.R. Frid M.G. El Kasmi K.C. McKinsey T.A. Sokol R.J. et al 2011. Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension. J. Immunol. 187: 2711-2722. 10.4049/jimmunol.1100479. 21813768.
42. Lishnevsky M. Haudek S.B. 2014. Epigenetic regulation of fibrocyte differentiation? J. Mol. Cell. Cardiol. 69: 85-87. 10.1016/j.yjmcc.2014.01.019. 24512845.
43. Lobera M. Madauss K.P. Pohlhaus D.T. Wright Q.G. Trocha M. Schmidt D.R. et al 2013. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat. Chem. Biol. 9: 319-325. 10.1038/nchembio.1223. 23524983.
44. Longworth M.S. Laimins L.A. 2006. Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src. Oncogene, 25: 4495-4500. 10.1038/sj.onc.1209473. 16532030.
45. Lu J. McKinsey T.A. Nicol R.L. Olson E.N. 2000 a. Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. Proc. Natl. Acad. Sci. U.S.A. 97: 4070-4075. 10.1073/pnas.080064097. 10737771.
46. Lu J. McKinsey T.A. Zhang C.L. Olson E.N. 2000 b. Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. Mol. Cell, 6: 233-244. 10.1016/S1097-2765(00)00025-3. 10983972.
47. Lundby A. Lage K. Weinert B.T. Bekker-Jensen D.B. Secher A. Skovgaard T. et al 2012. Proteomic analysis of lysine acetylation sites in rat tissues reveals organ specificity and subcellular patterns. Cell Rep. 2: 419-431. 10.1016/j.celrep.2012.07.006. 22902405.
48. McKinsey T.A. 2007. Derepression of pathological cardiac genes by members of the CaM kinase superfamily. Cardiovasc. Res. 73: 667-677. 10.1016/j.cardiores.2006.11.036. 17217938.
49. McKinsey T.A. 2011. Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart. J. Mol. Cell. Cardiol. 51: 491-496. 10.1016/j.yjmcc.2010.11.009. 21108947.
50. McKinsey T.A. 2012. Therapeutic potential for HDAC inhibitors in the heart. Annu. Rev. Pharmacol. Toxicol. 52: 303-319. 10.1146/annurev-pharmtox-010611-134712. 21942627.
51. McKinsey T.A. Zhang C.L. Lu J. Olson E.N. 2000 a. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature, 408: 106-111. 10.1038/35040593. 11081517.
52. McKinsey T.A. Zhang C.L. Olson E.N. 2000 b. Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc. Natl. Acad. Sci. U.S.A. 97: 14400-14405. 10.1073/pnas.260501497. 11114197.
53. McKinsey T.A. Zhang C.L. Olson E.N. 2001. Identification of a signal-responsive nuclear export sequence in class II histone deacetylases. Mol. Cell. Biol. 21: 6312-6321. 10.1128/MCB.21.18.6312-6321.2001. 11509672.
54. McLaughlin V.V. Archer S.L. Badesch D.B. Barst R.J. Farber H.W. Lindner J.R. et al 2009. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J. Am. Coll. Cardiol. 53: 1573-1619. 10.1016/j.jacc.2009.01.004. 19389575.
55. Methot J.L. Chakravarty P.K. Chenard M. Close J. Cruz J.C. Dahlberg W.K. et al 2008. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg. Med. Chem. Lett. 18: 973-978. 10.1016/j.bmcl.2007.12.031. 18182289.
56. Miska E.A. Karlsson C. Langley E. Nielsen S.J. Pines J. Kouzarides T. 1999. HDAC4 deacetylase associates with and represses the MEF2 transcription factor. EMBO J. 18: 5099-5107. 10.1093/emboj/18.18.5099. 10487761.
57. Monovich L. Vega R.B. Meredith E. Miranda K. Rao C. Capparelli M. et al 2010. A novel kinase inhibitor establishes a predominant role for protein kinase D as a cardiac class IIa histone deacetylase kinase. FEBS Lett. 584: 631-637. 10.1016/j.febslet.2009.12.014. 20018189.
58. Moradei O.M. Mallais T.C. Frechette S. Paquin I. Tessier P.E. Leit S.M. et al 2007. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J. Med. Chem. 50: 5543-5546. 10.1021/jm701079h. 17941625.
59. Morrell N.W. Adnot S. Archer S.L. Dupuis J. Jones P.L. MacLean M.R. et al 2009. Cellular and molecular basis of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54: S20-S31. 10.1016/j.jacc.2009.04.018. 19555855.
60. Mottet D. Castronovo V. 2010. Histone deacetylases: anti-angiogenic targets in cancer therapy. Curr. Cancer Drug Targets, 10: 898-913. 10.2174/156800910793358014. 20718701.
61. Nicolls M.R. Mizuno S. Taraseviciene-Stewart L. Farkas L. Drake J.I. Al Husseini A. et al 2012. New models of pulmonary hypertension based on VEGF receptor blockade-induced endothelial cell apoptosis. Pulm. Circ. 2: 434-442. 10.4103/2045-8932.105031. 23372927.
62. Oehme I. Deubzer H.E. Lodrini M. Milde T. Witt O. 2009. Targeting of HDAC8 and investigational inhibitors in neuroblastoma. Expert Opin. Investig. Drugs, 18: 1605-1617. 10.1517/14728220903241658. 19780707.
63. Olson D.E. Udeshi N.D. Wolfson N.A. Pitcairn C.A. Sullivan E.D. Jaffe J.D. et al 2014. An Unbiased Approach To Identify Endogenous Substrates of "Histone" Deacetylase 8. ACS Chem. Biol. 9: 2210-2216. 10.1021/cb500492r. 25089360.
64. Pandey U.B. Batlevi Y. Baehrecke E.H. Taylor J.P. 2007 a. HDAC6 at the intersection of autophagy, the ubiquitin-proteasome system and neurodegeneration. Autophagy, 3: 643-645. 10.4161/auto.5050. 17912024.
65. Pandey U.B. Nie Z. Batlevi Y. McCray B.A. Ritson G.P. Nedelsky N.B. et al. 2007 b. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature, 447: 860-864. 10.1038/nature05853. 17568747.
66. Pullamsetti S.S. Schermuly R. Ghofrani A. Weissmann N. Grimminger F. Seeger W. 2014. Novel and emerging therapies for pulmonary hypertension. Am. J. Respir. Crit Care Med. 189: 394-400. 10.1164/rccm.201308-1543PP. 24401129.
67. Roger V.L. Go A.S. Lloyd-Jones D.M. Benjamin E.J. Berry J.D. Borden W.B. et al 2012. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation, 125: e2-e220. 10.1161/CIR.0b013e31823ac046. 22179539.
68. Samant S.A. Courson D.S. Sundaresan N.R. Pillai V.B. Tan M. Zhao Y. et al 2011. HDAC3-dependent reversible lysine acetylation of cardiac myosin heavy chain isoforms modulates their enzymatic and motor activity. J. Biol. Chem. 286: 5567-5577. 10.1074/jbc.M110.163865. 21177250.
69. Sano M. Schneider M.D. 2004. Cyclin-dependent kinase-9: an RNAPII kinase at the nexus of cardiac growth and death cascades. Circ. Res. 95: 867-876. 10.1161/01.RES.0000146675.88354.04. 15514168.
70. Sano M. Abdellatif M. Oh H. Xie M. Bagella L. Giordano A. et al 2002. Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nat. Med. 8: 1310-1317. 10.1038/nm778. 12368904.
71. Shi J. Vakoc C.R. 2014. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell, 54: 728-736. 10.1016/j.molcel.2014.05.016. 24905006.
72. Silber J. Lim D.A. Petritsch C. Persson A.I. Maunakea A.K. Yu M. et al 2008. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 6: 14. 10.1186/1741-7015-6-14. 18577219.
73. Sparrow D.B. Miska E.A. Langley E. Reynaud-Deonauth S. Kotecha S. Towers N. et al 1999. MEF-2 function is modified by a novel co-repressor, MITR. EMBO J. 18: 5085-5098. 10.1093/emboj/18.18.5085. 10487760.
74. Spiltoir J.I. Stratton M.S. Cavasin M.A. Demos-Davies K. Reid B.G. Qi J. et al 2013. BET acetyl-lysine binding proteins control pathological cardiac hypertrophy. J. Mol. Cell. Cardiol. 63: 175-179. 10.1016/j.yjmcc.2013.07.017. 23939492.
75. Suzuki T. Ota Y. Ri M. Bando M. Gotoh A. Itoh Y. et al 2012. Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries. J. Med. Chem. 55: 9562-9575. 10.1021/jm300837y. 23116147.
76. Taraseviciene-Stewart L. Kasahara Y. Alger L. Hirth P. Mc Mahon G. Waltenberger J. et al 2001. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 15: 427-438. 10.1096/fj.00-0343com. 11156958.
77. Terbach N. Williams R.S. 2009. Structure-function studies for the panacea, valproic acid. Biochem. Soc. Trans. 37: 1126-1132. 10.1042/BST0371126. 19754465.
78. Valenzuela-Fernandez A. Cabrero J.R. Serrador J.M. Sanchez-Madrid F. 2008. HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol. 18: 291-297. 10.1016/j.tcb.2008.04.003. 18472263.
79. Vega R.B. Harrison B.C. Meadows E. Roberts C.R. Papst P.J. Olson E.N. McKinsey T.A. 2004. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol. Cell. Biol. 24: 8374-8385. 10.1128/MCB.24.19.8374-8385.2004. 15367659.
80. Walker L.A. Buttrick P.M. 2009. The right ventricle: biologic insights and response to disease. Curr. Cardiol. Rev. 5: 22-28. 10.2174/157340309787048077. 20066144.
81. Waltregny D. Glenisson W. Tran S.L. North B.J. Verdin E. Colige A. Castronovo V. 2005. Histone deacetylase HDAC8 associates with smooth muscle alpha-actin and is essential for smooth muscle cell contractility. FASEB J. 19: 966-968. 10.1096/fj.04-2303fje. 15772115.
82. Wang A.H. Bertos N.R. Vezmar M. Pelletier N. Crosato M. Heng H.H. et al 1999. HDAC4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor. Mol. Cell. Biol. 19: 7816-7827. 10523670.
83. Wang D. Zhang H. Li M. Frid M.G. Flockton A.R. McKeon B.A. et al 2013. MicroRNA-124 Controls the Proliferative, Migratory, and Inflammatory Phenotype of Pulmonary Vascular Fibroblasts. Circ. Res. 114: 67-78. 10.1161/CIRCRESAHA.114.301633. 24122720.
84. Williams S.M. Golden-Mason L. Ferguson B.S. Schuetze K.B. Cavasin M.A. Demos-Davies K. et al 2014. Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. J. Mol. Cell. Cardiol. 67: 112-125. 10.1016/j.yjmcc.2013.12.013. 24374140.
85. Wilson B.J. Tremblay A.M. Deblois G. Sylvain-Drolet G. Giguere V. 2010. An acetylation switch modulates the transcriptional activity of estrogen-related receptor alpha. Mol. Endocrinol. 24: 1349-1358. 10.1210/me.2009-0441. 20484414.
86. Wilson K.J. Witter D.J. Grimm J.B. Siliphaivanh P. Otte K.M. Kral A.M. et al 2008. Phenylglycine and phenylalanine derivatives as potent and selective HDAC1 inhibitors (SHI-1). Bioorg. Med. Chem. Lett. 18: 1859-1863. 10.1016/j.bmcl.2008.02.012. 18304810.
87. Witter D.J. Harrington P. Wilson K.J. Chenard M. Fleming J.C. Haines B. et al 2008. Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2). Bioorg. Med. Chem. Lett. 18: 726-731. 10.1016/j.bmcl.2007.11.047. 18060775.
88. Wolfson N.A. Ann P.C. Fierke C.A. 2013. HDAC8 substrates: Histones and beyond. Biopolymers, 99: 112-126. 10.1002/bip.22135. 23175386.
89. Wu Y. O'Callaghan D.S. Humbert M. 2013. An Update on Medical Therapy for Pulmonary Arterial Hypertension. Curr. Hypertens. Rep. 15: 614-622. 10.1007/s11906-013-0394-8. 24122306.
90. Xie M. Hill J.A. 2013. HDAC-dependent ventricular remodeling. Trends Cardiovasc. Med. 23: 229-235. 10.1016/j.tcm.2012.12.006. 23499301.
91. Yang Q. Dahl M.J. Albertine K.H. Ramchandran R. Sun M. Raj J.U. 2013. Role of histone deacetylases in regulation of phenotype of ovine newborn pulmonary arterial smooth muscle cells. Cell Prolif. 46: 654-664. 10.1111/cpr.12076. 24460719.
92. Yang Z. Yik J.H. Chen R. He N. Jang M.K. Ozato K. Zhou Q. 2005. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell, 19: 535-545. 10.1016/j.molcel.2005.06.029. 16109377.
93. Zhao L. Chen C.N. Hajji N. Oliver E. Cotroneo E. Wharton J. et al 2012. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation, 126: 455-467. 10.1161/CIRCULATIONAHA.112.103176. 22711276.